Thomas Jefferson University Hospital this week said it will offer Roche's Cobas 4800 BRAF V600 Mutation Test.

The hospital claimed that it is the first academic medical center in the US to provide the test, which was approved by the US Food and Drug Administration in August for use in determining which melanoma patients may benefit from treatment with Roche/Plexxikon's drug Zelboraf.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligences for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.